Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Anna Hagström

 

Gruppbild 314213

We focus on understanding the pathogenetic mechanisms underlying leukemogenesis with a special focus on infant leukemia. In particular we are interested in unravelling the biological mechanisms that drive clonal evolution, the emergence of drug resistance, and the role of tumor heterogeneity in these processes, ultimately leading to new effective therapies. We use a combination of state-of-the-art genomic methods, including whole genome, RNA and Exome sequencing as well as single-cell DNA and RNA-sequencing and leukemia mouse models in our work.

We are currently working on the following aims

  1. To identify the complement of genetic and epigenetic changes in KMT2A-R leukemia from infancy to adulthood and determine how they contribute to cellular transformation
  2. To determine the clinical impact of tumor heterogeneity at single-cell resolution
  3. To uncover clonal evolution in serial samples during treatment
  4. To study how therapy impact clonal evolution in leukemia mouse models

Full Publication list
 

Selected publications

FLT3N676K drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis. Hyrenius-Wittsten A, Pilheden M, Falqués-Costa A, Eriksson M, Sturesson H, Schneider P, Wander P, Garcia-Ruiz C, Liu J, Ågerstam H, Hultquist A, Lilljebjörn H, Stam RW, Järås M, and Hagström-Andersson AK. Leukemia. 2019 Apr 5. E-pub ahead of print

De novo activating mutations drive clonal evolution and enhances clonal fitness in KMT2A-rearranged leukemia. Hyrenius-Wittsten A, Pilheden M, Sturesson H, Hansson J, Walsh MP, Song G, Kazi J, Liu J, R Ramakrishan, C Garcia-Ruiz, Nance S, Gupta P, Zhang J, Rönnstrand L, Hultquist A, Downing JR, Lindkvist-Petersson K, Järås M, Gruber TA, Ma J, and Hagström-Andersson AK.  Nature Communications, 2018;9,1770.

Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia. Hyrenius-Wittsten A, Sturesson H, Bidgoli M, Jonson T, Ehinger M, Lilljebjörn H, Scheding S and Andersson AK. Genes Chromosomes and Cancer 2016;55;11:847-54.

The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias. Andersson AK#, Ma J#, Wang J, Chen X, Larson-Gedman A, Dang J, Nakitandwe J, Holmfeldt L, Parker M, Easton J, Huether R, Kriwacki R, Rusch M, Wu G, Li Y, Mulder M,  Raimondi S, Pounds S, Guolian K, Shi L, Becksfort J, Gupta P, Payne-Turner D, Vadodaria B, Boggs K, Yergeau D, Manne J, Song G, Edmonson M, Nagawatte P, Wei L, Cheng C, Pei D, Sutton R, Venn NC, Chetcuti A, Rush A, Catchpoole D, Heldrup J, Fioretos T, C Lu, Ding L, Pui CH, Shurtleff S, Mullighan CG, Mardis ER, Wilson RK, Gruber TA, Zhang J, Downing JR for the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project. # Contributed equally. Nat Genet, 47:330-337;2015.

IDH1 and IDH2 mutations in pediatric acute leukemia. Andersson A, Miller D, Lynch J, Lemoff A, Zhongling C, Pounds S, Radtke I, Bing Y, Schuetz J, Rubnitz J, Ribeiro R, Raimondi S, Zhang J,  Mullighan C, Shurtleff S, Schulman B, Downing J. Leukemia, 10:1570-7; 2011.

Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Andersson A, Ritz C, Lindgren D, Edén P, Lassen C, Heldrup J, Olofsson T, Råde J, Fontes M, Porwit-McDonald A, Behrendtz M, Höglund M, Johansson B, and Fioretos T. Leukemia, 6:1198-203;2007.

Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. Andersson A, Olofsson T, Lindgren D, Nilsson B, Ritz C, Edén P, Lassen C, Råde J, Fontes M, Mörse H, Heldrup J, Behrendtz M, Mitelman F, Höglund M, Johansson B, and Fioretos T. Proceedings of the National Academy of Sciences of the United States of America 102:19069-19074;2005.
 

Networks in academia

We are full members of the following strategic research program:

BioCARE (Swedish Research Council Strategic Research Program)

LUCC

 

Anna Hagström

Anna Hagström
Research group leader, Principal Investigator
Associate Professor, PhD

Department of Laboratory Medicine
Division of Clinical Genetics
BMC C13
SE-221 84 Lund
Sweden

+46 46 222 69 97
Anna [dot] Hagstrom [at] med [dot] lu [dot] se

Research group members
helena [dot] sturesson [at] med [dot] lu [dot] se (Helena Sturesson), PhD, Res Engineer
mattias [dot] pilheden [at] med [dot] lu [dot] se (Mattias Pilheden), PhD Student
ton [dot] falques [at] med [dot] lu [dot] se (Ton Falqués), Postdoc
louise [dot] ahlgren [at] med [dot] lu [dot] se (Louise Ahlgren), PhD Student

qirui [dot] zhang [at] med [dot] lu [dot] se (Qirui Zhang), Postdoc